Murae Organisor Limited

EARUM

INE060601023

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 08:00:41 18/05/2024 BST			5-day change	1st Jan Change
1.72 ^INR	+4.24%		+18.62%	+49.57%

04-24	Murae Organisor Limited Announces Board Appointments	CI
04-04	Murae Organisor Limited Appoints Sangita Rajpurohit as Company Secretary and Compliance Officer	CI

Earum Pharmaceuticals Limited Announces Resignation of Sanjaykumar Nai as Non-Executive Director

January 19, 2024 at 11:39 am

Earum Pharmaceuticals Limited announced the resignation of Mr. Sanjaykumar Nai as Non-Executive Director of the Company, effective January 19, 2024. Reason: Due to pre-occupation.

Latest news about Murae Organisor Limited

Murae Organisor Limited Announces Board Appointments	04-24	CI
Murae Organisor Limited Appoints Sangita Rajpurohit as Company Secretary and Compliance Officer	04-04	CI
Earum Pharmaceuticals Limited Approves Board Resignations	03-15	CI
Earum Pharmaceuticals' CFO Resigns	02-12	MT
Earum Pharmaceuticals Limited Announces Resignation of Sunil Kumar Patel as Chief Financial Officer	02-10	CI
Earum Pharmaceuticals Limited Approves Appointment of Vaghasiya Brijeshkumar Mathurbhai as Chief Financial Officer	02-09	CI
Earum Pharmaceuticals Limited Announces Change in Corporate Office Address	02-09	CI
Earum Pharmaceuticals Limited Announces Resignation of Sanjaykumar Nai as Non-Executive Director	01-19	CI
Earum Pharmaceuticals Limited Announces Resignation of Vijaykumar Patel as Managing Director	01-19	CI
Murae Organisor Names Managing Director	01-05	MT
Earum Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	12-09	CI
Earum Pharmaceuticals Limited Approves Board Changes	23/08/23	CI
Earum Pharmaceuticals Names CFO	15/08/23	MT
Earum Pharmaceuticals Limited Appoints Sunilkumar Patel as Chief Financial Officer	14/08/23	CI
Earum Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Earum Pharmaceuticals CFO Departs	10/08/23	MT
Earum Pharmaceuticals Limited Announces Executive Changes	09/08/23	CI
Earum Pharmaceuticals Limited Announces Change of Registered Office	09/08/23	CI
Payal Patel Resigns as Chief Financial Officer of Earum Pharmaceuticals Limited	09/08/23	CI
Earum Pharmaceuticals Limited Announces Resignation of Directors	08/08/23	CI
Earum Pharmaceuticals Limited Announces Resignation of Madhuri Mistry from the Position of the Company Secretary	02/08/23	CI
Earum Pharmaceuticals Limited's Board intends to launch an Equity Buyback on July 14, 2023	27/06/23	CI
Earum Pharmaceuticals Plans to Open Three Overseas Branches	26/06/23	MT
E Earum Pharmaceuticals Limited Approves the Proposal for Opening of Three Overseas Branch Offices	26/06/23	CI
Earum Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/05/23	CI

Murae Organisor Limited, formerly Earum Pharmaceuticals Limited, is an India-based pharmaceutical company. The Company is primarily engaged in marketing, trading and distribution of a range of pharmaceutical formulation products, such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti-cold drugs, analgesic/ anti-pyretic & anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants and injections. It offers a range of pharmaceutical formulation products, of which around 120 products are marketed by it under its own brand name. It also deals in the trading of active pharmaceutical ingredients (APIâs). Its products include HYGNEX+, HYGNEX+ Spray, EROLON and HYGNEX. It carries its business operations in Indian States, such as Gujarat, Maharashtra, Chhattisgarh, Uttar Pradesh, Mizoram, Andhra Pradesh, Rajasthan and others.

Sector

Pharmaceuticals

Calendar

01/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MURAE ORGANISOR LIMITED	+49.57%	4.89M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B